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Background:
To facilitate ease of swallowing and promote patient adherence, the U.S. Food and Drug 
Administration (FDA) has provided voluntary guidance for the size of generic drug tablets 
and capsules (1). This guidance recommends that generic products should not exceed 17 
millimeters (mm) in a single dimension. If a branded product already exceeds 17 mm, then 
the generic product should be no larger. No tablets or capsules should exceed 22 mm. 
Currently, no similar guidance for dietary supplements exists; however, supplements are 
implicated in swallowing problems, particularly among adults aged 65 years or older (2).
Objective:
To identify and characterize dietary supplement-associated swallowing problems in relation 
to pill size using data from 10 years of adverse event reports submitted to the FDA Center 
for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS).
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Methods and Findings:
The CAERS database contains FDA adverse event and product complaint reports for foods, 
dietary supplements, and cosmetics (2). The Dietary Supplement and Nonprescription Drug 
Consumer Protection Act (effective date for compliance: 22 December 2007) requires 
dietary supplement manufacturers, packers, and distributors to report serious adverse events 
to CAERS; voluntary reports may be submitted by healthcare professionals, consumers, and 
other members of the public (3). We used Medical Data Dictionary for Regulatory Activities 
(MedDRA) terminology to identify dietary supplement reports, submitted to CAERS from 1 
January 2006 through 31 December 2015, that involved swallowing problems (for example, 
choking and dysphagia). We extracted sex, age, product, and adverse event outcomes, and 
excluded 442 reports implicating either multiple supplement products or non-solid oral dose 
form products (for example, liquids or powders). We classified dietary supplement products 
by our dietary supplement product categorization, based on ingredients or common reasons 
for use (4). We measured pill (i.e., tablet or capsule) sizes for the 10 products most 
commonly identified.
Of 20 791 dietary supplement adverse event reports submitted to CAERS in 2006-2015, 
3962 (19.1%) indicated swallowing problems. These reports most commonly involved 
females (85.6%) (Table 1), representing 25.4% of all CAERS reports among females. 
Among the 64.5% of swallowing problem reports with age data, 76.8% were adults aged 65 
years or older.
Choking was the most frequently reported swallowing problem (86.0%), followed by foreign 
body trauma (7.8%). Based on CAERS medical reviewer assessment, 14.3% of swallowing 
problem reports cited serious adverse events, including three deaths attributed to 
supplement-induced airway obstruction or aspiration (5). Most swallowing problem reports 
involved multivitamins (72.9%); 17.3% involved calcium supplements.
The 10 most commonly reported dietary supplement products accounted for 3026 (76.4%) 
of swallowing problem reports (Table 2), with weighted mean pill length, width, and height 
of 19.3, 9.8, and 7.8 mm, respectively. The proportional reporting ratio (PRR) for 
swallowing problems from these 10 products was 12.7, indicating that the ratio of 
swallowing problem reports to reports for other problems was 12.7 times higher for these 10 
products than for other dietary supplements. Seven of the 10 products, accounting for 64.5% 
of all swallowing problem reports, were multivitamins marketed to older adults or calcium 
supplements. A single multivitamin product marketed to older women was involved in 
40.6% of swallowing problem reports.
Discussion:
Most dietary supplement swallowing problem reports involved multivitamins or calcium 
supplements which are used by up to 35% and 24% of older adults, respectively (5), who 
have higher rates than others for dysphagia and other swallowing issues (1). The 10 most 
commonly identified supplement products in swallowing problem reports all exceeded 17 
mm in length. Prevention opportunities include modifying supplement dose form 
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characteristics (e.g., producing smaller dose forms or adding coatings) and educating 
patients to speak with their pharmacists or physicians about benefits of supplements for 
them, and, if continued use would be beneficial, discuss ways to address problems 
swallowing pills.
This study has limitations: frequency of use of specific products was not available, CAERS 
reports may not be representative of the U.S. population, swallowing problems may be 
underreported, and completeness of reports can vary. Consequently, patient-specific risk 
factors for choking could not be fully assessed. Product pill sizes could have changed during 
or after the study period. Nevertheless, these data identify a specific harm, choking, that may 
be preventable, particularly for older adult patients who regularly consume dietary 
supplements.
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Table 1.
Dietary Supplement Swallowing Problem Adverse Event Reports to FDA, 2006-2015*
Case Characteristic Dietary Supplement Adverse Event 
Reports Involving Swallowing Problems, n 
(%) (n = 3962) †
Dietary Supplement Adverse 
Event Reports Not Involving 
Swallowing Problems, n (%) (n 
=16 829)
Sex
 Female 3390 (85.6) 9986 (59.3)
 Male 517 (13.0) 6101 (36.3)
 Not stated 55 (1.4) 742 (4.4)
Age, y
 <1 0 88 (0.5)
 1-4 21 (0.5) 143 (0.9)
 5-19 18 (0.5) 503 (3.0)
 20-44 103 (2.6) 3575 (21.2)
 45-64 450 (11.4) 3698 (22.0)
 65-74 643 (16.2) 1775 (10.5)
 75-84 825 (20.8) 1295 (7.7)
 ≥85 495 (12.5) 493 (2.9)
 Not stated 1407 (35.5) 5259 (31.3)
Report type‡
 Mandatory 3919 (98.9) 11 834 (70.3)
 Voluntary 43 (1.1) 4995 (29.7)
Reported outcome§
 Death 3 (0.1) 351 (2.1)
 Non-fatal, serious adverse events 563 (14.2) 6324 (37.6)
 Other adverse events 3396 (85.7) 10 154 (60.3)
Swallowing problem type‖
 Choking 3406 (86.0)
 Foreign body trauma 308 (7.8)
 Dysphagia 167 (4.2)
 Other swallowing problem types 81 (2.0)
Dietary supplement category¶
 Multivitamins 2889 (72.9)
 Calcium/bone health 687 (17.3)
 Pain or arthritis relief 93 (2.3)
 Cardiovascular health 67 (1.7)
 Other specified 67 (1.7)
 Immunity or infection/cold 50 (1.3)
 Single ingredient vitamins or minerals (not calcium) 48 (1.2)
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Case Characteristic Dietary Supplement Adverse Event 
Reports Involving Swallowing Problems, n 
(%) (n = 3962) †
Dietary Supplement Adverse 
Event Reports Not Involving 
Swallowing Problems, n (%) (n 
=16 829)
 Other categories 61 (1.5)
*
The term “dietary supplement” means a product (other than tobacco) intended to supplement the diet that bears or contains one or more of the 
following dietary ingredients: (A) a vitamin; (B) a mineral; (C) an herb or botanical; (D) an amino acid; (E) a dietary substance for use by man to 
supplement the diet by increasing the total dietary intake; or (F) a concentrate, metabolite, constituent, extract, or combination of any ingredient 
described in clause (A), (B), (C), (D), or (E) [21 U.S.C. § 321(f)(f)] (4).
†
Dietary supplement adverse event reports indicating swallowing problems were identified by the following Medical Dictionary for Regulatory 
Activities (MedDRA) preferred terms: aspiration, choking, choking sensation, drooling, dysphagia, foaming at mouth, foreign body, foreign body 
aspiration, foreign body trauma, laryngitis, esophageal discomfort, esophageal injury, esophageal obstruction, esophageal spasm, esophagitis, 
pharyngeal injury, oropharyngeal discomfort, and sensation of foreign body. Reports involving more than one dietary supplement product, or 
involving non-solid oral dosage forms (e.g., powders, liquids, inhalants), were excluded (n = 442).
‡
If both a voluntary and a mandatory report were submitted for the same event, the event was included here as “Mandatory.”
§Serious outcomes are death; a life-threatening experience, inpatient hospitalization, a persistent or significant disability or incapacity; congenital 
anomaly; and a medical or surgical intervention required to prevent the previous outcomes [Public Law 109-462] (https://www.congress.gov/109/
plaws/publ462/PLAW-109publ462.pdf). Other adverse events include non-serious illness/injury; other serious (important medical events); visit to a 
health provider; and visit to emergency room.
‖Other swallowing problem types: choking sensation (n = 49 reports), pharyngeal injury (n = 11), foreign body aspiration (n = 7), esophageal 
obstruction (n = 4), esophageal injury (n = 3), foreign body (n = 2), oropharyngeal discomfort (n = 2), sensation of foreign body (n = 2), and 
aspiration (n = 1).
¶Other dietary supplement categories: bodybuilding, detoxification or cleansing, energy, laxative, microbial additive (probiotics); sexual 
enhancement; skin or hair health; sleep, sedation or anxiolysis and weight loss (2).
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Table 2.
Pill Sizes of 10 Products Commonly Identified in Dietary Supplement Swallowing Problem Adverse Event 
Reports to FDA, 2006-2015*
Dietary Supplement Product† Dietary Supplement Reports 
Involving Swallowing Problems, 
n (n = 3962)
Proportional Reporting 
Ratio (PRR)
Pill Dimensions, mm
Length Width Height
Multivitamin, Older Females,‡ Product 1 1607 6.8 19.0 10.0 8.0
Multivitamin, Older Persons, Product 1 332 2.7 18.5 9.5 7.3
Multivitamin, Females, Product 1 188 3.2 21.5 9.0 7.8
Calcium Supplement, Product 1 185 3.9 21.0 11.0 8.5
Calcium Supplement, Product 2 161 3.9 20.5 10.0 7.5
Multivitamin, Females, Product 2 145 4.4 18.5 9.5 7.5
Multivitamin, Males, Product 1 138 3.6 19.0 8.5 7.0
Multivitamin, Older Females, Product 2 99 4.1 19.5 10.0 7.5
Multivitamin, Older Males, Product 1 86 2.7 19.5 10.0 7.0
Calcium Supplement, Product 3 85 2.4 20.0 9.8 7.0
All 10 products§ 3026 12.7 19.3 9.8 7.8
mm = millimeter.
*
Pill sizes were measured by photographing products purchased at a community U.S. pharmacy in 2016-2017 with an adjacent mm ruler using a 
Nikon 3200 camera secured in a rigid camera stand, magnifying the photographs and measuring dimensions to the nearest millimeter.
†
Dietary supplement product description was based on product label.
‡
“Older” refers to ages 50 years and older.
§
Pill dimensions for all 10 products are weighted means.
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